Synchrony Financial SYF

Financial Services · Financial - Credit Services · Synthos Deep Dive · 2026-07-03

$78.05

Buy — Tactical

—

The Overview

Synchrony is the company behind the store credit cards at places like Lowe's, Amazon, PayPal, and the CareCredit card you might use at the dentist or vet. It lends money to shoppers and earns interest — a lot of it — plus fees. It is very profitable right now (it keeps about 18 cents of every revenue dollar) and it is cheap: you're paying about $8 for every $1 of annual profit, versus $15–$25 for a typical big company.

The catch is what kind of company it is. Synchrony lends to a lot of middle- and lower-credit-score shoppers, so when the economy weakens and people stop paying their card bills, its profits can fall hard and fast. That's the trade-off: cheap price, bumpy ride.

Our verdict is Buy — Tactical, meaning: worth owning for the cheap price and the big cash it hands back to shareholders (dividends plus a huge buyback), but treat it as a cyclical trade you size carefully, not a set-and-forget core holding.

Here's what our three scores mean in everyday terms:

Downside Risk 5/10 (middle). The price is cheap and the balance sheet has more cash than debt, which cushions you — but the stock swings more than the market and its fortunes ride the consumer-credit cycle.
Growth Quality 5/10 (average). Profits per share are rising, but mostly because the company is shrinking its share count with buybacks — the underlying business (loans outstanding) is basically flat.
Exponential Potential 3/10 (low). This is a mature lender in a crowded market. Don't expect it to multiply; expect steady cash back.

The one big worry: a US recession or a jump in unemployment would push more borrowers to miss payments, and Synchrony's earnings would drop sharply.

Putting a number on it: our fair-value estimate is $94 against a current price of $78.05 — real upside if our numbers are right.

Target entry zone $77 – $78 accumulate in this band; ideal adds on a dip toward the 50-day average near $77, keeping roughly a 17% margin below our $94 base-case fair value

Our summary metrics

Downside Risk (lower = safer)5/10Moderate

Cheap at 8× EPS and net-cash, but 1.32 beta and deep consumer-credit cyclicality — this is a subprime-tilted lender.

Growth Quality5/10Moderate

15% forward EPS CAGR is real, but it's buyback-driven — revenue is flat and loan receivables are not growing.

Exponential Potential3/10Low

A mature $26B credit-card lender in a saturated market; no acceleration, no TAM story — this is a value/return-of-capital name, not an exponential.

Fair value$94 $63–$114

What does “fair value” mean?

Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.

The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.

What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)

Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.

Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.

WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.

HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.

AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

Exponential Potential

Exponential Potential3/10Low

A mature $26B credit-card lender in a saturated market; no acceleration, no TAM story — this is a value/return-of-capital name, not an exponential.

What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.

Deeper analysis

Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.

Check our number Market-implied growth ≈ 12%/yr This isn’t how we calculate fair value — it’s public math you can verify yourself. To justify today’s $78, earnings would have to compound roughly 12% a year for 10 years (9% discount rate). Analysts forecast ~12%/yr, so the market is pricing in about what the Street expects.

Reference table

Street consensus	$89.75 (high $100 / low $81; 25 Buy · 15 Hold · 1 Strong Sell) — context, not our anchor
Valuation	8.2× trailing EPS · 8.2× FY26E · 7.3× FY27E · 1.59× book · net-cash balance sheet
Technicals	Neutral-to-mildly-positive — $76, −14% off 52-wk high, just above 50/200-DMA, RSI 64, lagging SPY (+12% vs +21% 12-mo)
Conviction	Low — zero Synthos expert voices; call rests on quant + fundamentals only
Position sizing	Tactical/value satellite, ~1.5–3%, sized for a cyclical (not a core hold)

What the experts actually said

No independent expert claims in the Synthos knowledge base yet for SYF — this dive is fundamentals- and technicals-driven, not panel-driven.

Price & moving averages 12 months · 50 & 200-day averages · 52-week range

Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.

Bollinger Bands 20-day average ± 2 standard deviations

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

RSI (14) momentum gauge · 0–100

Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 49.

MACD 12 / 26 / 9 · trend & momentum

The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.

Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago

Solid = SYF · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$78.05

Market cap$25B

P/E trailing7×

P/E FY26E / FY27E8× / 7×

EV / Sales1.2×*

EV / EBITDA4.5×*

Gross margin52.3%

Net margin18.6%

Dividend yield1.59%

Beta1.311

52-wk range$64 – $88

RSI(14)50

50 / 200-DMA$77 / $75

12-mo return+3% (SPY +19%)

Street target$88 ($80–$104)

Analyst grades25 Buy · 15 Hold · 0 Sell

FMP ratingA-

Next earnings2026-07-21 (Q2'26 earnings; Street EPS est $2.11)

* Enterprise value recomputed in-house: the data vendor nets cash but omits short-term investments, overstating EV for cash-rich balance sheets. EV multiples marked * use market cap + total debt − cash − short-term investments.

1. What it is

Synchrony Financial (NYSE: SYF) is the largest US provider of private-label and co-branded credit cards and point-of-sale consumer financing, spun out of GE in 2014. It partners with retailers, healthcare providers, and merchants to issue store-branded and co-branded cards, and funds the loans mostly with an online consumer bank (deposits are ~83% of funding). Fiscal year ends December 31.

The business is organized around five sales platforms: Home & Auto, Digital (Amazon, PayPal, Venmo), Health & Wellness (the CareCredit / Pets Best / Care franchise used at dentists, vets, audiologists), Diversified & Value (Lowe's, Sam's Club, Walmart.com), and Lifestyle (apparel, luxury, powersports, jewelry). CareCredit is the crown jewel — a genuinely differentiated, sticky healthcare-financing niche.

Revenue & scale (FY2025, from filings):

Total revenue (interest + fees) $19.1B; net interest income $18.5B. FMP does not provide product- or geographic-segment revenue tables for SYF (seg_prod and seg_geo are empty), so the platform mix below is drawn from management's own Q1'26 earnings release (§9).
Loan receivables ~$100.1B, essentially flat year-over-year — the defining fact of the current story. Purchase volume rose 6% to $43.0B in Q1'26, but higher customer payment rates kept the loan book from growing.
Geography: effectively 100% United States — a domestic consumer-credit pure-play, with all the US-macro and US-regulatory (CFPB/late-fee) exposure that implies.

The key structural feature: Synchrony shares economics with its retail partners through Retailer Share Arrangements (RSAs) — when a program performs well (low charge-offs), partners take a bigger cut, which dampens both the upside and the downside of credit swings.

2. The expert thesis (none — stated plainly)

There is no expert coverage of SYF in the Synthos knowledge base. total_claims = 0, net-bullish voices = 0. No podcast, letter, or tracked investor in our panel has made a traceable, distilled claim on this name.

That means this note carries no borrowed conviction. Everything below is derived from (a) the reported financials and live analyst estimates (FMP), (b) management's own dated earnings-release guidance (SEC 8-K, half-weighted, §9), and (c) our own quant scoring. Where a comparable name in our coverage would show a claim_id here, SYF shows nothing — and per house standard we say so rather than manufacture a thesis.

Implication for conviction: the verdict is Low conviction by construction. A cheap, well-understood cyclical can still be a good tactical buy on the numbers alone — but absent an expert edge, we size it as a satellite and lean on the margin of safety in the valuation, not on a differentiated view.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

Score	0–10	The read
Downside Risk (lower = safer)	5 · Moderate	8× earnings, 1.59× book and a net-cash balance sheet give a real valuation floor, but beta 1.32, a subprime-tilted book (Q1'26 net charge-offs 5.42%) and full consumer-credit cyclicality cut the other way. Cheap ≠ safe here.
Growth Quality	5 · Average	Forward EPS CAGR ~15% ($9.29 FY26E → ~$12.80 FY29E) and ROE ~19–21% are genuinely good — but revenue is flat-to-down and loan receivables aren't growing, so the EPS growth is mostly buyback-manufactured, not franchise expansion.
Exponential Potential	3 · Low	A mature $26B lender in a saturated US card market. No acceleration (revenue growth is negative on the FMP net-interest basis), no TAM runway, no optionality. This is a value/return-of-capital name, full stop.

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.

Case	Key assumptions	Fair value
Bull	Credit normalizes benignly, charge-offs keep falling, purchase-volume growth reaccelerates loan receivables; the $6.5B buyback shrinks share count ~8%+. FY27E EPS beats to ~$11.50; multiple re-rates to ~10× as the market pays for durable ~20% ROE.	~$114 (+49%)
Base (our anchor)	Estimates roughly hit — FY27E EPS ~$10.50; flat loan book, steady credit, buyback drives the EPS line. A cyclical-but-cheap lender earns a ~9× multiple.	~$94 (+23%)
Bear	Recession / unemployment shock: net charge-offs re-spike toward 7%+, provisioning jumps, EPS falls to ~$8–9; multiple de-rates to ~7× as the market prices the cycle.	~$63 (−17%)

Synthos fair value = the base case, ~$94 (+23%), with the full $63–$114 span as the honest range. Note how wide and skewed that range is — that width is the cyclicality, not indecision. Our base sits just above the Street's $89.75 consensus; our bear ($63) is below the Street low ($81) because we take a genuine credit downturn more seriously than the sell-side does at cycle-mid. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). SYF is neither an exponential nor really a compounder — it is a cyclical value/capital-return name:

Forward growth: on FMP's net-interest-revenue basis, revenue is flat-to-declining (FY25 $15.0B → FY29E $17.0B on the estimate line; reported total revenue was $19.1B). EPS CAGR of ~15% (FY25 $9.35 → FY29E $12.80) is real but is driven by share-count shrinkage, not a bigger business — diluted shares fell from ~423M (FY23) to ~346M (Q1'26), and a fresh $6.5B buyback (~25% of the market cap) continues that.
Acceleration (2nd derivative): none. Loan receivables are flat at ~$100B; purchase-volume growth (+6% in Q1'26) is being absorbed by higher payment rates. This is a steady-state business, not an accelerating one.
Room to run: the US private-label card market is mature and saturated. There is no large untapped TAM here — growth comes from partner wins (Harbor Freight, Walmart.com CareCredit acceptance) and share gains at the margin, not category expansion.
Return of capital IS the story: ~$1.0B returned in Q1'26 alone ($900M buyback + $104M dividends), a 13% dividend hike to $0.34/qtr from Q3'26, and the no-expiration $6.5B buyback. That's a shareholder-yield thesis, not an exponential one.

Exponential Potential: Low (3/10). Own SYF for cheapness + a shrinking share count + a fat capital return — explicitly not for a multibagger. Honest framing keeps it out of any "next-exponential" flagship sleeve.

5. Financials (real numbers — FMP annual/quarterly)

Revenue: FY25 total revenue $19.1B (net interest income $18.5B); FY24 $20.8B. The headline moves with rate and accounting geography — the operational tell is the flat ~$100B loan book, not the revenue line.
Earnings: net income $3.55B FY25 (EPS $9.35, diluted $9.29), up from $3.50B / $8.64 in FY24 — modest net-income growth, faster EPS growth thanks to buybacks. Q1'26 net earnings $805M, EPS $2.27 (+20% YoY on EPS, +6% on net income — the buyback wedge in one line).
Margins & returns: net margin ~18% TTM, ROE ~19–21%, ROA 2.7% (Q1'26) — strong for a lender. Net interest margin 15.50% (a very high, subprime-consistent NIM).
Credit quality (the key metric for this business): Q1'26 net charge-offs 5.42% (down 96 bps YoY — credit is improving off the 2024 peak); 30+ day delinquencies 4.54%; allowance for credit losses 10.42% of receivables. Improving credit is the current tailwind; a reversal is the thesis risk.
Cash flow: operating cash flow $9.85B FY25 (FMP reports FCF equal to OCF; a lender has negligible traditional capex). Amply funds the dividend and buyback.
Balance sheet: total assets $119B, deposits ~$83B (83% of funding), CET1 12.7% (well-capitalized), total debt $15.2B against $15.0B cash → net cash of ~$0.2B, net-debt/EBITDA −0.8×. Book value/share ~$45.29; the stock trades at 1.59× book.

6. Valuation — priced in or room?

SYF is genuinely cheap on every earnings-based metric: 8.2× trailing EPS, 8.2× FY26E, 7.3× FY27E, 1.59× book, ~13.8% earnings yield. For a business earning ~20% ROE, a high-single-digit P/E and ~1.6× book embeds a lot of cycle pessimism. The bull case is simple: a flat-to-modestly-rising EPS line, a 25%-of-cap buyback, and a ~2% dividend can deliver a low-double-digit total return even with no multiple re-rating at all — and any re-rate toward ~10× is upside.

The bear case is equally simple and is why it's cheap: this is a subprime-tilted, single-country consumer lender, and the market rationally refuses to pay a high multiple for earnings that can halve in a recession. The low P/E is a cyclical discount, not a free lunch.

Reverse read: at $76 on ~$10.50 FY27E EPS, the market is paying ~7.3× — i.e. pricing roughly no net growth and some credit deterioration. That's a favorable setup if credit stays benign. Street targets (context): consensus $89.75, high $100, low $81 — our $94 base is a touch above consensus (we credit the buyback math), and our $63 bear sits below the Street low because the sell-side under-weights tail credit risk. Not a compounder-at-a-fair-price; a cheap cyclical with a margin of safety buy.

7. Technicals (from the tech block)

Trend: neutral-to-mildly-constructive. $76.33 sits just above the 50-DMA ($73.60) and 200-DMA ($74.27), with the two moving averages tightly clustered — a flattish, range-bound tape, not a strong trend either way.
Location: −13.7% off the 52-week high ($88.77) and +19.7% off the 52-week low ($63.08) — mid-range, with a meaningful max drawdown from peak (−13.7%). No stretched-entry problem.
Momentum: RSI(14) 64 — firm but not overbought (<70); MACD +1.36 (mildly positive).
Relative strength (the tell): SYF is a laggard — +12.0% 12-mo vs SPY +20.6% and QQQ +30.3%, and −9.5% over 6 months while SPY was +8.4%. It has underperformed both the market and growth peers, consistent with a value name the market has left behind.
Read: technicals are neutral — no momentum wind at your back, but no breakdown either. This is a valuation/fundamentals buy, not a technical-breakout buy; the lagging RS is part of why the price is cheap.

8. Moat & competitive position

SYF's competitive position is moderate and niche-dependent. Its durable edge is deep retailer/partner integration — multi-year private-label programs (Lowe's, Sam's Club, Amazon, PayPal) with high switching costs for the partner, plus the genuinely differentiated CareCredit healthcare-financing network (used at 250k+ providers, now extending to Walmart.com and Sam's Club health/wellness). The RSA structure aligns partners and shares credit risk, which is sticky. But the broader private-label card market is competitive (Bread Financial, Citi Retail, Capital One, Amex partner deals), programs are periodically re-bid, and the whole model is exposed to CFPB late-fee rules and the consumer-credit cycle. Call it a narrow, cyclical moat — real in CareCredit, contestable elsewhere.

Peer set (FMP-listed, market cap): Morgan Stanley $337B, Truist $64B, Fifth Third $52B, ORIX $43B, KB Financial $39B, M&T Bank $35B, Shinhan $32B, Banco Bradesco $31B, W.R. Berkley $27B. (Note: FMP's peer list here is a grab-bag of banks/financials, not clean card-lender comps — Synchrony's truest public comparables are Bread Financial, American Express, Capital One and Discover, which are absent from this list.) Against the listed group, SYF's ~8× P/E and ~20% ROE screen as high-return, low-multiple — the classic cyclical-value profile.

9. Management, capital allocation & guidance

Capital allocation: shareholder-return-first and aggressive. Q1'26 returned ~$1.0B ($900M buyback + $104M dividends); the Board approved a new $6.5B buyback with no expiration date (~25% of the market cap) starting Q2'26, and a planned 13% dividend increase to $0.34/quarter from Q3'26. With a net-cash balance sheet and CET1 12.7%, this is well-covered — the return-of-capital thesis is credible, not stretched.
Insider activity: the recent Form 4s are routine director/officer equity awards and dividend-equivalent accruals (e.g. director grants at $76.05 on 2026-06-30), not open-market discretionary buying or selling — no signal either way in the sampled window.
Management's own guidance (half-weighted — their book): from the SEC 8-K earnings release dated 2026-04-21 (Q1'26), management's forward-looking commentary is qualitative rather than a hard full-year EPS target: CEO Brian Doubles cited "record first quarter purchase volume," "sequential improvement in average active account trends," and a focus on "driving momentum forward" across the five platforms; CFO Brian Wenzel highlighted "sequential acceleration in purchase volume growth and positive inflection in ending loan receivables growth… while maintaining our credit discipline amid an uncertain macroeconomic backdrop." Reported Q1'26 operating metrics: NIM 15.50% (+76 bps), efficiency ratio 35.6%, ROA 2.7%, ROE 19.5%, ROTCE 24.5%. Treat this as management's self-interested framing (half-weight): it is real and dated, but it is a positive gloss on a flat loan book, and there was no explicit numeric full-year outlook in the release.

10. Catalysts & what to watch

Next earnings: 2026-07-21 (Q2'26; Street EPS $2.11, revenue est ~$3.73B). The lines that matter: net charge-off rate (is the improvement continuing?), loan-receivables growth (does the book finally inflect positive?), and purchase-volume trend.
Buyback pace: how fast the $6.5B authorization shrinks the share count — the direct driver of the EPS story.
Credit cycle / macro: US unemployment and delinquency trends; a re-acceleration of net charge-offs is the single biggest swing factor.
Regulatory: CFPB credit-card late-fee rule status and any PPPC (promotional/pricing) offset dynamics.
Partner wins/renewals: program adds and re-bids (recent: Harbor Freight, Miracle-Ear, Walmart.com CareCredit acceptance).

Thesis tripwires (what would change the call): two consecutive quarters of rising net charge-offs; loan receivables shrinking rather than inflecting; a sharp macro/unemployment deterioration; or a major partner loss. Any of these flips this from tactical-buy to avoid.

11. Key risks

Consumer-credit cyclicality (structural, the big one): a recession or unemployment spike drives charge-offs and provisioning up fast; SYF's subprime tilt (NIM 15.5%, NCOs 5.4%) magnifies the swing. Earnings can fall sharply in a downturn.
Single-country, single-product concentration: ~100% US, essentially all consumer credit-card lending — no geographic or business-line diversification to cushion a US consumer shock.
Flat underlying growth: the loan book isn't growing; if the buyback ever slows, the EPS growth story largely stops.
Regulatory / political: CFPB late-fee rules, potential rate caps, and PBM-style scrutiny of medical financing (CareCredit) are live overhangs.
Partner concentration & re-bid risk: losing or repricing a large program (or a partner's own financial distress) hits a whole platform.
No expert edge: with zero Synthos KB coverage, this call has no differentiated qualitative signal — it rests entirely on valuation and quant, which lowers conviction.

12. Verdict, position sizing & monitoring

Buy — Tactical. SYF is a well-run, highly profitable (~20% ROE), cheap (8× EPS, 1.6× book, net-cash) consumer lender handing back ~25% of its market cap via buyback plus a rising dividend, with credit currently improving. That's a legitimately attractive risk/reward at $76 with a base-case fair value of ~$94 (+23%). But it is a deeply cyclical, single-country, subprime-tilted card lender with no expert coverage and no franchise growth — so this is a valuation-and-capital-return trade, not a core compounder.

Sizing: tactical/value satellite, ~1.5–3% — sized for cyclicality and the low-conviction (no-expert) profile. Scale in; keep dry powder for a credit-driven drawdown, which is where the real bargain would appear.
Monitoring: re-underwrite every earnings print on the credit metrics in §10; the thesis is a bet that credit stays benign while the buyback compounds per-share value. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $76.33.
Single biggest risk: the consumer-credit cycle — a recession spikes charge-offs and the cheap multiple is cheap for a reason.

Provenance & disclosures

Traceability: 0 KB claims — there is no Synthos expert coverage for SYF. The verdict is fundamentals- and quant-driven only; no expert conviction is claimed or borrowed. Fabricated conviction is structurally impossible (claim-ID reconciliation; here there are simply no claims to cite).
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from SEC 8-K dated 2026-04-21. Forward figures are analyst consensus (FMP) or our own scenario model, labeled as estimates.
Management caveat: the §9 guidance is management's own earnings-release language, half-weighted by design and qualitative (no hard numeric full-year outlook was provided).
Data note: FMP's revenue-estimate line for SYF is on a net-interest basis and differs from reported total revenue ($19.1B FY25); segment tables (seg_prod/seg_geo) were empty and platform mix was sourced from management's release. FMP's peer list is bank-heavy and omits SYF's truest card-lender comps.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").